Research Article
The Effects of Noncompliance to Prolia (Denosumab) on the Changes in Bone Mineral Density: A Retrospective Review
Table 1
Participant baseline characteristics stratified by time of denosumab injection.
| | Characteristic | Time of subsequent injection of denosumab | | <5 months | 5–7 months | >7 months |
| | Sample size () | 12 | 365 | 59 | | Age, years, mean (SD) | 67.50 (9.59) | 68.35 (10.62) | 64.34 (11.20) | | Women, % () | 91.67% (11) | 92.6% (338) | 91.53% (54) | | Proton pump inhibitor (PPI) use, % () | 27.27% (3) | 26.30% (96) | 22.03% (13) | | Selective serotonin reuptake inhibitor (SSRI) use, % () | 0.00% (0) | 6.85% (25) | 7.02% (4) | | Serotonin-norepinephrine reuptake inhibitor (SNRI) use, % () | 0.00% (0) | 1.37% (5) | 5.17% (3) | | Tricyclic antidepressant (TCA) use, % () | 9.09% (1) | 4.11% (15) | 5.17% (3) | | BMD, mean (SD) | | | | | Lumbar spine | 0.850 (0.149) | 0.800 (0.131) | 0.808 (0.101) | | Femoral neck | 0.629 (0.043) | 0.623 (0.100) | 0.619 (0.100) | | History of nonvertebral fracture, % () | 41.67% (5) | 55.34% (202) | 49.15% (29) | | History of vertebral fracture, % () | 16.67% (2) | 23.56% (86) | 22.05% (13) |
|
|
